TREATMENT OF VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME

• Main Authors: VALENTIN-TORRES Alice, TING Anthony E, JENKINS Eric D
• Format: Patent
• Language: English; Spanish
• Published: 14.02.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV- 2). La invención se refiere a un método para tratar el síndrome de distrés respiratorio agudo (ARDS) inducido por virus, por medio de la administración a un sujeto con el ARDS inducido por virus de células progenitoras adultas multipotentes (MAPCs), que son células madre no embrionarias, no germinales que tienen un amplio potencial de diferenciación y extendida capacidad de replicación; el virus que induce el ARDS puede ser un Betacoronavirus, tal como el síndrome respiratorio agudo grave (SARS), Corona Virus o Síndrome Respiratorio de Oriente Medio (MERS), Corona Virus del síndrome respiratorio agudo grave 2 (SARS-CoV-2).